89 related articles for article (PubMed ID: 31204939)
1. [Effect of Carfilzomib on Proliferation and Apoptosis of Mantle Cell Lymphoma Cells].
Jiang GX; Li DY; Chen M; Liu YC; Chen JX; Shi XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):827-832. PubMed ID: 31204939
[TBL] [Abstract][Full Text] [Related]
2. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib Inhibits Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells and Leads to the Induction of Apoptosis.
Zhang YL; Guang MH; Zhuo HQ; Min XH; Yao Q; Gu AQ; Wu SH; Zhang DB; Lu JY; Chen Y; Chen YH; Zhang KJ
Acta Haematol; 2017; 137(2):106-112. PubMed ID: 28208145
[TBL] [Abstract][Full Text] [Related]
4. [Effects of Decitabine Combined with Bortezomib on the Proliferation of Mantle Cell Lymphoma Cell Lines and Its Underling Mechanisms].
Zhang JN; Qiao SK; Chen D; Xing LN; Li Y; Guo XN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1197-1204. PubMed ID: 32798398
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome.
Zhang L; Pham LV; Newberry KJ; Ou Z; Liang R; Qian J; Sun L; Blonska M; You Y; Yang J; Lin X; Rollo A; Tamayo AT; Lee J; Ford RJ; Zhao X; Kwak LW; Yi Q; Wang M
Mol Cancer Ther; 2013 Nov; 12(11):2494-504. PubMed ID: 23990113
[TBL] [Abstract][Full Text] [Related]
7. [PLK1 Expression in Mantle Cell Lymphoma and Its Clinical Significance].
Shen LY; Lin CM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):833-838. PubMed ID: 31204940
[TBL] [Abstract][Full Text] [Related]
8. Reactive oxygen species mediate cancer stem-like cells and determine bortezomib sensitivity via Mcl-1 and Zeb-1 in mantle cell lymphoma.
Luanpitpong S; Poohadsuan J; Samart P; Kiratipaiboon C; Rojanasakul Y; Issaragrisil S
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3739-3753. PubMed ID: 30251692
[TBL] [Abstract][Full Text] [Related]
9. Drug Repurposing Screen Identifies Novel Classes of Drugs with Anticancer Activity in Mantle Cell Lymphoma.
Han C; Yu X; Zhang C; Cai Y; Cao Y; Wang S; Shen J
Comb Chem High Throughput Screen; 2019; 22(7):483-495. PubMed ID: 31526347
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
Cowan AJ; Frayo SL; Press OW; Palanca-Wessels MC; Pagel JM; Green DJ; Gopal AK
Anticancer Drugs; 2015 Oct; 26(9):974-83. PubMed ID: 26237500
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
[TBL] [Abstract][Full Text] [Related]
13. [Antiproliferative Effect of Specific Inhibitor XAV939 for β-catenin on MCL Jeko-1 Cells].
He JS; Huang YQ; Weng JM; Xiao LY; Weng KZ; Ma XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):411-5. PubMed ID: 25948195
[TBL] [Abstract][Full Text] [Related]
14. Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.
Milani V; Lorenz M; Weinkauf M; Rieken M; Pastore A; Dreyling M; Issels R
Int J Hyperthermia; 2009 Jun; 25(4):262-72. PubMed ID: 19670095
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.
Wang M; Han XH; Zhang L; Yang J; Qian JF; Shi YK; Kwak LW; Romaguera J; Yi Q
Leukemia; 2008 Jan; 22(1):179-85. PubMed ID: 17898787
[TBL] [Abstract][Full Text] [Related]
17. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
Nguyen T; Parker R; Zhang Y; Hawkins E; Kmieciak M; Craun W; Grant S
BMC Cancer; 2018 Nov; 18(1):1129. PubMed ID: 30445933
[TBL] [Abstract][Full Text] [Related]
18. Mucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma.
Wang X; Shirazi F; Yan W; Liu X; Wang H; Orlowski RZ; Wang H
J Cell Mol Med; 2021 Nov; 25(21):10164-10174. PubMed ID: 34651428
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
